Telaprevir-based triple therapy significantly decreases the serum alpha-fetoprotein level in chronic hepatitis C patients: A prospective study - Telaprevir-based triple therapy and serum alpha-fetoprotein level for chronic hepatitis C

Department of General Internal Medicine, Kyushu University Hospital0 个研究点目标入组 200 人开始时间: 2014年4月22日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•The exclusion criteria were as follows: (1) presence of HCC at enrollment, or development of HCC until 24 weeks after EOT; (2) shortening of treatment due to adverse effect, virological breakthrough, non-virological response (NVR), or dropout; (3) in dual therapy group, extension of standard 48-week therapy; (4) inadequate treatment dose of 80% or less assigned total cumulative dosage of each drug; (5) positivity for antibody to human immunodeficiency virus or positivity for hepatitis B surface antigen; (6) clinical or biochemical evidence of hepatic decompensation (Child-Pugh B or C, ascites, bleeding varices, or encephalopathy) at enrollment; (7) excessive active alcohol consumption (a daily intake of more than 60g of alcohol) or drug abuse; (8) other forms of liver disease (e.g., autoimmune hepatitis, alcoholic liver disease, hemochromatosis); or (9) treatment with antiviral or immunosuppressive agents prior to enrollment.

发起方

Department of General Internal Medicine, Kyushu University Hospital